Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches

Executive Summary

A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
Advertisement

Related Content

EU Court Cuts Perindopril Fines For Krka And Servier
Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze
Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes
Amazon Offers Hope As US Pricing Approaches ‘Pain Point’ For Manufacturers, Says Lupin
Lupin Primes For Specialty Future With Symbiomix Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124630

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel